Journal

Blood Neoplasia

2950-3280 · Elsevier BV

108 verified public works

Browse all journals →

Prognostic impact of age and MDS-associated mutations in NPM1-mutated AML

2026 · 0 citations

IMiD/CELMoD resistance in myeloma is associated with changes in lipid metabolism that may be targetable

2026 · 0 citations

CPX-351 plus gemtuzumab ozogamicin in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome

2026 · 0 citations

Single-cell sequencing reveals transcriptional and immunogenetic diversity in stereotyped chronic lymphocytic leukemia

2026 · 0 citations

Excess body weight at diagnosis is associated with inferior ALL outcomes in male adolescents in the ALL-BFM 2000 study

2026 · 0 citations

IMiD-based monotherapy for maintenance of remission in primary CNS lymphoma: a single-center experience

2026 · 0 citations

Abnormal serum immunofixation patterns are common after BCMA CAR-T in multiple myeloma and are preceded by immune events

2026 · 0 citations

Fixed-treatment duration venetoclax following covalent BTKi progression in chronic lymphocytic leukemia

2026 · 0 citations

Olfactory receptors as tumor suppressors in cutaneous T-cell lymphoma via p38γ pathway modulation

2025 · 0 citations

Clarithromycin, ixazomib, pomalidomide, dexamethasone for relapsed/refractory myeloma: survival and correlative analysis

2025 · 0 citations

Phase 2 trial of daratumumab, cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma

2025 · 0 citations

Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm

2025 · 0 citations

TYK2 is essential for the therapeutic effect of IFN-α in Jak2V617F-induced murine myeloproliferative neoplasms

2025 · 0 citations

Tumor-associated myeloid cells support murine T-ALL in the central nervous system via integrin signaling

2025 · 0 citations

Risk factors and clinical impact of cytomegalovirus DNAemia in patients with multiple myeloma treated with teclistamab

2025 · 0 citations

Reduced CD20 expression yields inferior survival in patients with B-cell lymphoma treated with CD20×CD3 antibodies

2025 · 0 citations

Quality of life, fatigue, depression, attention deficits, and pain after childhood Langerhans cell histiocytosis

2025 · 0 citations

Ambroxol induces myeloma cell death by inhibiting autophagy

2025 · 0 citations

A novel cereblon variant with both exon 8 and 10 deletions in newly diagnosed and relapsed multiple myeloma

2025 · 0 citations

Magnetic resonance spectroscopy–based detection of response to therapy targeting glutaminolysis in lymphoma

2025 · 0 citations

Outcomes at a single institution with MTR induction and consolidation in the management of primary CNS lymphoma

2025 · 0 citations

Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm

2025 · 0 citations

New leads to enhance tagraxofusp efficacy in pDC-AML

2025 · 0 citations

Characterization of fusion transcripts in AML without recurrent genetic abnormalities unravels new putative fusion genes

2025 · 0 citations

A feedforward loop between ACLY and MYC supports T-ALL progression in vivo

2025 · 0 citations

Targeting transcription-replication conflicts using G-quadruplexes stabilizers in multiple myeloma

2025 · 0 citations

Race and age disparities in randomized trials of acute myeloid leukemia: a systematic review and meta-analysis

2025 · 0 citations

A phase 2 study of decitabine with or without carboplatin and arsenic trioxide in patients with MDS and AML

2025 · 0 citations

Clonal composition of karyotypically normal AML at diagnosis is not affected by the microenvironment

2025 · 0 citations

Driver mutations in myeloid and lymphoid cells point to multipotent progenitor origin of diverse histiocytic neoplasms

2025 · 0 citations